Ketamine, a trauma analgesic with sex-specific immunomodulatory function

Choi, KwangH; Spencer, HaleyF; Berman, RinaY; Boese, Martin

doi:10.4103/1673-5374.358617

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies on animals have revealed distinct gender diferences in ketamine's mechanism of action. Zarate Jr. et al [36] found that female rats require only half the minimum dose of males to produce antidepressant efects, which suggested that there are gender diferences in the mechanism of action of ketamine [23]. As confrmed by Carrier and Kabbaj [37], female rats are more sensitive to ketamine because they are sensitive to low doses of ketamine (2.5 mg/kg) compared with male rats.…”

Section: Discussionmentioning

confidence: 98%

“…Tere were diferences in the efcacy of ketamine in the treatment of depression between genders [22,23], and there may also be gender diferences in the occurrence of drug adverse events (AEs). A randomized controlled study showed that the most common adverse events in patients treated with ketamine were nausea, separation, and dizziness, and the incidence of adverse events was higher in women than in men [24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gender Differences in Adverse Events of Ketamine Drugs: A Real-World Study Based on FAERS

Zhang,

Guo,

Zhang

et al. 2024

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

Objective. To identify gender differences in the adverse events (AEs) of ketamine, reduce the AEs among patients, and contribute to the advancement of personalized medicine. Methods. A normalized dataset from 2004 Q1 to the 2022 Q4 in the US Food and Drug Administration Adverse Event Reporting System (FAERS) was analysed. The reporting odds ratio (ROR), proportional reporting ratio (PRR), and P value were used to detect the risk signals from the data in the FAERS database and quantify the presence and extent of gender differences in ketamine AEs. Results. Totally, 5,477 ketamine (female/male (2507/1795)) AE reports were analysed, and sedation (ROR 1.30 (1.07, 1.58)), suicidal ideation (ROR 1.30 (1.03, 1.64)), nausea (ROR 1.37 (1.05, 1.78)), depression (ROR 1.22 (1.13, 1.61)), dizziness (ROR 2.25 (1.78, 2.90)), anxiety (ROR 1.48 (1.09, 1.99)), and other adverse events were found to be significantly more frequent in male patients than in female patients. Conclusion. Using FAERS, we identified gender as factors associated with ketamine-related AEs. With the limitations inherent to this open data source, our data need prospective validation but elucidate potential factors for a personalized side effect profiling.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Gender Differences in Adverse Events of Ketamine Drugs: A Real-World Study Based on FAERS

Zhang,

Guo,

Zhang

et al. 2024

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

Perioperative Ketamine and Cancer Recurrence: A Comprehensive Review

Rodriguez Arango,

Zec,

Khalife

2024

JCM

View full text Add to dashboard Cite

Cancer is a significant global health threat and a leading cause of death worldwide. Effective early-stage interventions, particularly surgery, can potentially cure many solid tumors. However, the risk of postoperative cancer recurrence remains high. Recent research highlights the influence of perioperative anesthetic and analgesic choices on the fate of residual cancer cells, potentially affecting recurrence risks. Among these agents, ketamine—a well-known anesthetic and analgesic—has garnered interest due to its antitumor properties, mainly through inhibiting the N-methyl-D-aspartate (NMDA) receptor found in various cancer tissues. Additionally, ketamine’s potential immunomodulatory effects, given the expression of NMDA receptors on immune cells, suggest that it plays a significant role during the perioperative period. This review synthesizes current evidence on ketamine’s impact on cancer cell biology, inflammation, immune modulation, and the role of the gut microbiota, proposing ketamine as a promising agent for enhancing oncological outcomes.

show abstract

Ketamine, a trauma analgesic with sex-specific immunomodulatory function

Cited by 2 publications

References 13 publications

Gender Differences in Adverse Events of Ketamine Drugs: A Real-World Study Based on FAERS

Gender Differences in Adverse Events of Ketamine Drugs: A Real-World Study Based on FAERS

Perioperative Ketamine and Cancer Recurrence: A Comprehensive Review

Contact Info

Product

Resources

About